This English version of the Blog is no longer updated.
You can find all the news on the Italian Blog and use the automatic translation tool.
- David Healy, professor1,
- Dee Mangin, professor2
- Author affiliations
- 1Department of Psychiatry, Bangor University, Wales
- 2Department of Family Medicine, McMaster University, Ontario
- Correspondence to: david.healy54@googlemail.com
Immediately on taking a selective serotonin reuptake inhibitor (SSRI), most people have some genital anaesthesia.1
This may be aggravated on withdrawal of the drug and can remain for
years after treatment has stopped, constituting post-SSRI sexual
dysfunction (PSSD).2 The first case of
PSSD was reported to regulators in 1987, even before fluoxetine was
approved. While sexual dysfunction features in the labels of SSRIs,
neither genital anaesthesia nor PSSD does. The fluoxetine label states
that “there are no adequate and well-controlled studies examining sexual
dysfunction with fluoxetine treatment.” The citalopram label
acknowledges “some evidence suggests that SSRIs can cause such untoward
sexual experiences.”
A standard refrain is that
randomised clinical trials of short duration and small size have limited
ability to detect rare effects of drugs, implying that longer trials
are all that’s needed. But as indicated by the sexual effects of SSRIs,
which are more common than their mood effects,1
a possibly greater problem lies not in whether we can detect rare
adverse events but in our limited ability to detect common ones.
Fetishising RCTs as medicine’s only true tool for establishing
drug-effect relations may be one reason for this problem.
In 1962, in the wake of the thalidomide disaster, RCTs—a then poorly understood technique brought into the mainstream by the English epidemiologist Austin Bradford Hill—were adopted in amendments to the US Federal Food, Drug, and Cosmetic Act to buttress the safety of medicines by keeping ineffective drugs off the market, even though Bradford Hill’s landmark RCT of streptomycin offered less information on the drug’s benefits and side effects than prior clinical …
The gold standard way to miss adverse events
In 1962, in the wake of the thalidomide disaster, RCTs—a then poorly understood technique brought into the mainstream by the English epidemiologist Austin Bradford Hill—were adopted in amendments to the US Federal Food, Drug, and Cosmetic Act to buttress the safety of medicines by keeping ineffective drugs off the market, even though Bradford Hill’s landmark RCT of streptomycin offered less information on the drug’s benefits and side effects than prior clinical …
https://www.bmj.com/content/367/bmj.l5777
https://www.ncbi.nlm.nih.gov/pubmed/31578186
